JLE

Epileptic Disorders

MENU

Preliminary efficacy of levetiracetam in children Volume 5, supplément 1, Supplement, May 2003

1. Pellock JM, Appleton R. Use of new antiepileptic drugs in the treatment of childhood epilepsy. Epilepsia 1999; 40(Suppl 6): S29-38.

2. Shields WD. Catastrophic epilepsy in childhood. Epilepsia 2000; 41(Suppl 2): S2-6.

3. Amann JP, Dulac O. Trials in children. Epilepsy Res 2001; 45: 133-6.

4. Dulac O, Guerrini R. Seizure types and syndromes: lumping or splitting. Epilepsy Res 2001; 45: 37-40.

5. Pellock JM. Treatment of seizures and epilepsy in children and adolescents. Neurology 1998; 51(Suppl 4): S8-14.

6. Pellock JM. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999; 104: 1106-16.

7. Pellock JM. Drug treatment in children. In: Engel J Jr, Pedley TA. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers, 1997: 1205-10.

8. Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001; 21: 1375-88.

9. Glauser TA, Pellock JM, Bebin EM. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43: 518-24.

10. Harden C. Safety profile of levetiracetam. Epilepsia 2001; 42(Suppl 4): 36-9.

11. Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol 2002; 17(Suppl 1): S70-5.

12. Kaminska A, Ickowicz A, Plouin P, et al. Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15-29.

13. Doose H. Myoclonic-astatic epilepsy. Epilepsy Res 1992; 6(Suppl): 163-8.

14. de los Reyes EC, Sharp GB, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Ann Neurol 2001; 50(Suppl 1): S108.

15. Berg AT, Shinnar S, Levy SR, et al. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999; 40: 445-52.

16. Bebin M. Pediatric partial and generalized seizures. J Child Neurol 2002; 17(Suppl 1): S65-9.

17. Barron TF, Faircloth VC, Yuncker LA, et al. Levetiracetam adjunct therapy for refractory pediatric generalized epilepsies. Epilepsia 2001; 42(Suppl 7): 53.

18. Bourgeois BFD, Holder DL, Valencia I, et al. Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia 2001; 42(Suppl 7): 53-4.

19. Mandelbaum DE, Kugler SL, Wenger EC, et al. Clinical experience with levetiracetam and zonisamide in children with uncontrolled epilepsy. Epilepsia 2001; 42(Suppl 7): 182.

20. Ng Y, Wheless JW. Levetiracetam: pediatric experience. Epilepsia 2001; 42(Suppl 7): 55-6.

21. Gustafson MC, Ritter FJ, Frost MD, et al. Clinical experience with levetiracetam treating refractory, symptomatic seizures in children. Epilepsia 2001; 42(Suppl 7): 55.

22. Hovinga C, Morris H, Holland K, et al. Levetiracetam efficacy in adults and children. Epilepsia 2001; 42(Suppl 7): 213.

23. Strunc MJ, Levisohm PM. Tolerability and efficacy of levetiracetam in children. Epilepsia 2001; 42(Suppl 7): 92.

24. Faircloth VC, Hunt SL, Yuncker LA, et al. Levetiracetam adjunctive therapy for refractory pediatric focal-onset epilepsy. Epilepsia 2001; 42(Suppl 7): 54.

25. Wannag E, Eriksson A-S, Brockmeier K. Tolerability of levetiracetam in children with refractory epilepsy. Epilepsia 2001; 42(Suppl 7): 57.

26. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611-13.

27. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574-79.

28. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.

29. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf 1996; 15: 378-93.

30. Glauser TA. Expending first-line therapy options for children with partial seizures. Neurology 2000; 55(Suppl 3): S30-7.